Ameliorating Methylglyoxal-Induced Progenitor Cell Dysfunction for Tissue Repair in Diabetes

Area of Science:

• Cell Biology
• Endocrinology
• Regenerative Medicine

Background:

• Diabetes impairs patient-derived progenitor cell (PC) function, but molecular triggers remain unclear.
• Methylglyoxal (MGO), a reactive dicarbonyl species from hyperglycemia, is implicated in PC dysfunction.
• Glyoxalase 1 (GLO1) scavenges MGO, potentially reversing PC dysfunction.

Purpose of the Study:

• To investigate if GLO1 can reverse methylglyoxal-induced bone marrow-derived PC (BMPC) dysfunction.
• To determine if GLO1 augments inositol-requiring enzyme 1α (IRE1α) activity in BMPCs.
• To assess the therapeutic potential of GLO1 for diabetic wound healing.

Main Methods:

• Isolated BMPCs from diabetic (db/db) and control (db/+) mice.
• Exposed BMPCs to MGO and assessed dysfunction; rescued with GLO1 overexpression.
• Analyzed IRE1α expression and activity in BMPCs.
• Utilized a diabetic mouse cutaneous wound model for in vivo studies.
• Administered GLO1-overexpressing cells and GLO1 inducers (trans-resveratrol, hesperetin) in vivo.

Main Results:

• MGO induced severe BMPC dysfunction (impaired network formation, migration, proliferation; increased apoptosis), which was rescued by GLO1.
• MGO attenuated IRE1α expression and activation, effects reversed by GLO1.
• MGO directly inhibited IRE1α RNase activity in vitro.
• GLO1 overexpression in diabetic cells accelerated wound closure and enhanced angiogenesis in vivo.
• Adenovirus-mediated GLO1 transfer and small-molecule inducers improved wound healing and angiogenesis in diabetic mice.

Conclusions:

• GLO1 rescues BMPC dysfunction and promotes diabetic wound healing, partly by preventing MGO-induced IRE1α impairment.
• Targeting MGO with GLO1 offers a novel therapeutic strategy for improving PC-mediated angiogenesis and tissue repair in diabetes.